Ulf Mark Schneider (born 9 September 1965) is a German/American businessman, and the CEO of Nestlé. He is the former CEO of Fresenius, a €28 billion global healthcare group.
Schneider was born and raised in Neuwied, Germany, and became a US citizen in 2003. He holds a doctorate in economics from the University of St. Gallen, Switzerland, and an MBA from Harvard Business School.
Schneider was group finance director for Gehe UK plc., a pharmaceutical wholesale and retail distributor, in Coventry, England. Schneider held several senior executive positions starting in 1989 with Gehe's majority shareholder, Franz Haniel & Cie. GmbH, a diversified German industrial company.
Schneider joined Fresenius in November 2001, when he was appointed chief financial officer of Fresenius Medical Care. From May 2003 until June 2016 he served as CEO of the parent company Fresenius. Under Schneider's leadership of Fresenius, the number of employees more than tripled, revenue quadrupled and net income increased twelvefold. While Schneider was CEO, Fresenius also carried out a number of major strategic acquisitions: the private hospital chain HELIOS Kliniken in 2005; US dialysis provider Renal Care Group, in 2006; US pharmaceutical company APP Pharmaceuticals, in 2008; Liberty Dialysis, another major dialysis provider in the US, in 2011; and, in 2014, the purchase of 41 hospitals from Rhön-Klinikum, through which HELIOS became the largest private hospital operator in Germany.
In June 2016, Schneider was appointed CEO of Nestlé SA, replacing Paul Bulcke. He started as CEO in January 2017. Schneider is the first outsider to run Nestlé since 1922.
The management challenges of global growth and future strategies in the healthcare and pharmaceutical industries are of particular interest to Schneider.
Schneider chaired the European advisory board of Harvard Business School until 2016 and served on the board of directors of the American chemical company DuPont from 2014 to 2017.
Schneider speaks German, English, and French.